Journal article

Glycolipid-peptide vaccination induces liver-resident memory CD8( ) T cells that protect against rodent malaria

Lauren E Holz, Yu Cheng Chua, Maria N de Menezes, Regan J Anderson, Sarah L Draper, Benjamin J Compton, Susanna TS Chan, Juby Mathew, Jasmine Li, Lukasz Kedzierski, Zhongfang Wang, Lynette Beattie, Matthias H Enders, Sonia Ghilas, Rose May, Thiago M Steiner, Joshua Lange, Daniel Fernandez-Ruiz, Ana Maria Valencia-Hernandez, Taryn L Osmond Show all

SCIENCE IMMUNOLOGY | AMER ASSOC ADVANCEMENT SCIENCE | Published : 2020

Abstract

Liver resident-memory CD8+ T cells (TRM cells) can kill liver-stage Plasmodium-infected cells and prevent malaria, but simple vaccines for generating this important immune population are lacking. Here, we report the development of a fully synthetic self-adjuvanting glycolipid-peptide conjugate vaccine designed to efficiently induce liver TRM cells. Upon cleavage in vivo, the glycolipid-peptide conjugate vaccine releases an MHC I-restricted peptide epitope (to stimulate Plasmodium-specific CD8+ T cells) and an adjuvant component, the NKT cell agonist α-galactosylceramide (α-GalCer). A single dose of this vaccine in mice induced substantial numbers of intrahepatic malaria-specific CD8+ T cells..

View full abstract